Clinical trials: Fibromyalgia
Fibromyalgia
Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia
This is a Phase 3, multi-center, 52-week, open-label trial to evaluate the long-term safety and efficacy of AXS-14 in the management of fibromyalgia.
- Trial name
- NCT07637162
- Testing
- AXS-14 (esreboxetine)
- Where
- 35 sites in United States
- Volunteers
- 300 people
- Sponsor
- Axsome Therapeutics, Inc.
Mitochondrial Diseases, Myalgic Encephalomyelitis Chronic Fatigue Syndrome
The Precision Mito- Mito Map COMPASS Study
Mito Map is a research tool that produces an Energy Score from information provided by a participant. This remote observational study has an initial enrollment target of 400 adults across seven prespecified cohorts: healthy…
- Conditions
- Mitochondrial Diseases, Myalgic Encephalomyelitis Chronic Fatigue Syndrome, Post-COVID-19 Condition, Postural Orthostatic Tachycardia Syndrome
- Trial name
- COMPASS (NCT07856121)
- Testing
- Mito Map Energy Score and Home Functional Assessments
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- AI Agent Vault, Inc. d/b/a Precision Mito
Migraine, Fibromyalgia
The Effect of Remote Electrical Neuromodulation (REN) on Conditioned Pain Modulation (CPM) in Migraine and Fibromyalgia
Migraine and Fibromyalgia (FM) are chronic pain disorders characterized by altered central pain processing and impaired endogenous pain inhibition.
- Conditions
- Migraine, Fibromyalgia, Conditioned Pain Modulation
- Trial name
- NCT07841509
- Testing
- Remote Electrical Neuromodulation (REN) device
- Where
- 2 sites in United States, Israel
- Volunteers
- 120 people
- Sponsor
- Theranica
Cerebral Palsy, Multiple Sclerosis
The EXOPULSE Study - a Database for Routine Follow-up of Clinical Outcomes
The objective is to explore the potential short and long-term impact of the EXOPULSE Mollii Suit and EXOPULSE Suit on subjects with CP, MS, stroke, fibromyalgia or other neurologic disorders which may cause such types of…
- Conditions
- Cerebral Palsy, Multiple Sclerosis, Stroke, Neurologic Disorder
- Trial name
- EXOREG (NCT05901259)
- Testing
- EXOPULSE Mollii Suit and EXOPULSE Suit
- Where
- Sweden
- Volunteers
- 200 people
- Sponsor
- Otto Bock Healthcare Products GmbH
Fibromyalgia
Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design
The study is a Phase 3, double-blind, placebo-controlled, randomized withdrawal study to assess the efficacy and safety of AXS-14 in the management of fibromyalgia.
- Trial name
- FORWARD (NCT07398417)
- Testing
- AXS-14 (Esreboxetine)
- Where
- 53 sites in United States
- Volunteers
- 620 people
- Sponsor
- Axsome Therapeutics, Inc.
Fibromyalgia
Ultrasonic Neuromodulation of Cingulate Cortex for Fibromyalgia
The goal of this clinical trial is to evaluate a new noninvasive brain stimulation intervention for fibromyalgia and to determine its effectiveness in reducing pain.
- Trial name
- NCT07226648
- Testing
- Focused Ultrasound
- Where
- 8 sites in United States
- Volunteers
- 180 people
- Sponsor
- SPIRE Therapeutics Inc.
Fibromyalgia (FM)
EEG Prediction and Clinical Efficacy of tDCS in Fibromyalgia.
The purpose of this randomized controlled trial is to investigate the non-inferiority, and possible superiority, of a high-dose home-based tDCS protocol compared with a conventional home-based protocol, and to assess its…
- Trial name
- FM-TDCS-PREDIC (NCT07583056)
- Testing
- High-dose home-tDCS M1, Conventional home-tDCS, High-dose home-tDCS DLPFC
- Where
- Spain
- Volunteers
- 250 people
- Sponsor
- Ionclinics & Deionic SL
Fibromyalgia
A Clinical Study of ONO-1110 in Patients With Fibromyalgia
To Evaluate the Efficacy and Safety of ONO-1110 in Patients with Fibromyalgia
- Trial name
- NCT06752590
- Testing
- ONO-1110
- Where
- 30 sites in Japan
- Volunteers
- 175 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Fibromyalgia, Pain, Chronic
Effectiveness of the Sana Device on Fibromyalgia Symptoms
This is study designed to confirm the effectiveness of the Sana Device in patients with pain due to fibromyalgia on quality of life as measured by the Fibromyalgia Impact Questionnaire Revised (FIQR).
- Conditions
- Fibromyalgia, Pain, Chronic, Quality of Life
- Trial name
- NCT05394610
- Testing
- Sana Device, Sana Device (Control)
- Sponsor
- Sana Health
Primary Body Region (Arranged Most Common to Least), Lumbar/SI
ATI Evidence-based Guide Investigating Clinical Services
The goal of this study is to evaluate how standard-of-care outpatient rehabilitation is delivered and how variation in care delivery mechanisms relates to clinical outcomes, service utilization, and value in patients receiving…
- Conditions
- Primary Body Region (Arranged Most Common to Least), Lumbar/SI, Knee, Shoulder
- Trial name
- AEGIS (NCT02285868)
- Where
- United States
- Volunteers
- 4,000,000 people, healthy volunteers welcome
- Sponsor
- ATI Holdings, LLC
Fibromyalgia
A Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects With Fibromyalgia
The purpose of this study was to assess analgesic efficacy of ASP8062 relative to placebo as well as the safety and tolerability.
- Trial name
- NCT03092726
- Testing
- ASP8062
- Where
- 24 sites in United States
- Volunteers
- 183 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Fibromyalgia
A Proof-of-concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia Syndrome
The purpose of the study is to evaluate efficacy and safety of rozanolixizumab to treat adult study participants with severe fibromyalgia syndrome (FMS).
- Trial name
- NCT05643794
- Testing
- rozanolixizumab
- Where
- 7 sites in United Kingdom
- Volunteers
- 63 people
- Sponsor
- UCB Biopharma SRL
Fibromyalgia, Myofascial Pain Syndromes
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
The present trial is designed to assess the safety and efficacy of TNX-102 SL 2.8 mg tablets, taken daily at bedtime after 12 weeks of treatment in patients with fibromyalgia.
- Conditions
- Fibromyalgia, Myofascial Pain Syndromes, Muscular Diseases, Nervous System Diseases
- Trial name
- RE-AFFIRM (NCT02829814)
- Testing
- TNX-102 SL Tablet, 2.8 mg
- Where
- 32 sites in United States
- Volunteers
- 51 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Primary Fibromyalgia
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
This is a Phase 3, open-label, extension trial designed to evaluate the long term safety and efficacy over 3 months of TNX-102 SL tablets taken daily at bedtime for the treatment of Fibromyalgia (FM).
- Trial name
- NCT02589275
- Testing
- TNX-102 SL Tablet 2.8 mg
- Where
- 33 sites in United States
- Volunteers
- 375 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Fibromyalgia, Myofascial Pain Syndromes
A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia
The use of low-dose CBP dosed nightly at bedtime for FM was supported by the results of Tonix' TNX-CY-F202 Phase 2b study (also referred to as the BESTFIT Study).
- Conditions
- Fibromyalgia, Myofascial Pain Syndromes, Muscular Diseases, Musculoskeletal Diseases
- Trial name
- AFFIRM (NCT02436096)
- Testing
- TNX-102 SL Tablet, 2.8mg
- Where
- 35 sites in United States
- Volunteers
- 519 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Fibromyalgia
A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia
This is a Phase 3, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken daily at bedtime for the treatment of…
- Trial name
- RESILIENT (NCT05273749)
- Testing
- TNX-102 SL Tablet, 5.6 mg
- Where
- 33 sites in United States
- Volunteers
- 457 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Major Depressive Disorder, Fibromyalgia
Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial
The primary objective of this study is to provide duloxetine to investigators for the treatment of patients who have previously participated in neuroscience duloxetine clinical trials and for whom effective alternative therapy is…
- Conditions
- Major Depressive Disorder, Fibromyalgia, Diabetic Peripheral Neuropathic Pain, Generalized Anxiety Disorder
- Trial name
- NCT00071708
- Testing
- Duloxetine Hydrochloride
- Where
- 13 sites in Australia
- Sponsor
- Eli Lilly and Company
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable
Quest to Analyze One Thousand Humans Meditating
This study will be focused on assessing the molecular, physiological, and emotional correlates of an intensive meditation experience in the context of a retreat setting in a large 2000 plus-person cohort comprised of healthy and…
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma
- Trial name
- QUANTUM (NCT06583395)
- Testing
- Advanced multi-component meditation practice
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Tobias Moeller-Bertram
Fibromyalgia
A Study to Assess the Analgesic Efficacy and Safety of ASP0819 in Patients With Fibromyalgia
This study assessed analgesic efficacy of ASP0819 relative to placebo as well as the safety and tolerability. This study assessed treatment differences in physical function as well as the improvements in overall subject status…
- Trial name
- NCT03056690
- Testing
- ASP0819
- Where
- 24 sites in United States
- Volunteers
- 186 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences